guest ::
| Home > Publications database > Improved Tau PET SUVR Quantification in 4-Repeat Tau Phenotypes with [18F]PI-2620 > print |
| Home > Publications database > Improved Tau PET SUVR Quantification in 4-Repeat Tau Phenotypes with [18F]PI-2620 > print |
| 001 | 1030418 | ||
| 005 | 20250203133200.0 | ||
| 024 | 7 | _ | |a 10.2967/jnumed.123.265930 |2 doi |
| 024 | 7 | _ | |a 0097-9058 |2 ISSN |
| 024 | 7 | _ | |a 0022-3123 |2 ISSN |
| 024 | 7 | _ | |a 0161-5505 |2 ISSN |
| 024 | 7 | _ | |a 1535-5667 |2 ISSN |
| 024 | 7 | _ | |a 2159-662X |2 ISSN |
| 024 | 7 | _ | |a 10.34734/FZJ-2024-05291 |2 datacite_doi |
| 024 | 7 | _ | |a 38575191 |2 pmid |
| 024 | 7 | _ | |a WOS:001251294600021 |2 WOS |
| 037 | _ | _ | |a FZJ-2024-05291 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Bischof, Gérard N. |0 P:(DE-Juel1)166265 |b 0 |e Corresponding author |u fzj |
| 245 | _ | _ | |a Improved Tau PET SUVR Quantification in 4-Repeat Tau Phenotypes with [18F]PI-2620 |
| 260 | _ | _ | |a New York, NY |c 2024 |b Soc. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1738136589_6367 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a We used a new data-driven methodology to identify a set of reference regions that enhanced the quantification of the SUV ratio of the second-generation tau tracer 2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c′]dipyridine ([18F]PI-2620) in a group of patients clinically diagnosed with 4-repeat tauopathy, specifically progressive supranuclear palsy or cortical basal syndrome. The study found that SUV ratios calculated using the identified reference regions (i.e., fusiform gyrus and crus-cerebellum) were significantly associated with symptom severity and disease duration. This establishes, for the first time to our knowledge, the suitability of [18F]PI-2620 for tracking disease progression in this 4-repeat disease population. This is an important step toward increased clinical utility, such as patient stratification and monitoring in disease-modifying treatment trials. Additionally, the applied methodology successfully optimized reference regions for automated detection of brain imaging tracers. This approach may also hold value for other brain imaging tracers. |
| 536 | _ | _ | |a 5253 - Neuroimaging (POF4-525) |0 G:(DE-HGF)POF4-5253 |c POF4-525 |f POF IV |x 0 |
| 536 | _ | _ | |a 5254 - Neuroscientific Data Analytics and AI (POF4-525) |0 G:(DE-HGF)POF4-5254 |c POF4-525 |f POF IV |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Brendel, Matthias |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Barthel, Henryk |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Theis, Hendrik |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Barbe, Michael |0 P:(DE-Juel1)131613 |b 4 |
| 700 | 1 | _ | |a Bartenstein, Peter |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Claasen, Joseph |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Danek, Adrian |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Höglinger, Günter |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Levin, Johannes |0 P:(DE-HGF)0 |b 9 |
| 700 | 1 | _ | |a Marek, Ken |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Neumaier, Bernd |0 P:(DE-Juel1)166419 |b 11 |u fzj |
| 700 | 1 | _ | |a Palleis, Carla |0 P:(DE-HGF)0 |b 12 |
| 700 | 1 | _ | |a Patt, Marianne |0 P:(DE-HGF)0 |b 13 |
| 700 | 1 | _ | |a Rullmann, Michael |0 P:(DE-HGF)0 |b 14 |
| 700 | 1 | _ | |a Saur, Dorothee |0 P:(DE-HGF)0 |b 15 |
| 700 | 1 | _ | |a Schroeter, Matthias L. |0 P:(DE-HGF)0 |b 16 |
| 700 | 1 | _ | |a Seibyl, John |0 P:(DE-HGF)0 |b 17 |
| 700 | 1 | _ | |a Song, Mengmeng |0 P:(DE-HGF)0 |b 18 |
| 700 | 1 | _ | |a Stephens, Andrew |0 P:(DE-HGF)0 |b 19 |
| 700 | 1 | _ | |a Sabri, Osama |0 P:(DE-HGF)0 |b 20 |
| 700 | 1 | _ | |a Drzezga, Alexander |0 P:(DE-Juel1)177611 |b 21 |u fzj |
| 700 | 1 | _ | |a van Eimeren, Thilo |0 P:(DE-Juel1)169110 |b 22 |
| 773 | _ | _ | |a 10.2967/jnumed.123.265930 |g Vol. 65, no. 6, p. 952 - 955 |0 PERI:(DE-600)2040222-3 |n 6 |p 952 - 955 |t Journal of nuclear medicine |v 65 |y 2024 |x 0097-9058 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/1030418/files/Improved%20Tau%20PET%20SUVR%20Quantification%20in%204-Repeat%20Tau%20Phenotypes%20with%20%5B18F%5DPI-2620.pdf |y OpenAccess |z StatID:(DE-HGF)0510 |
| 909 | C | O | |o oai:juser.fz-juelich.de:1030418 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)166265 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 11 |6 P:(DE-Juel1)166419 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 21 |6 P:(DE-Juel1)177611 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5253 |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5254 |x 1 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-10-24 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-24 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NUCL MED : 2022 |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2025-01-01 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-01-01 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b J NUCL MED : 2022 |d 2025-01-01 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-5-20090406 |k INM-5 |l Nuklearchemie |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-2-20090406 |k INM-2 |l Molekulare Organisation des Gehirns |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-Juel1)INM-5-20090406 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-2-20090406 |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|